Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Johnson & Johnson’s Yuvanci recommended by CHMP to treat pulmonary arterial hypertension

The rare form of pulmonary hypertension affects around 30,000 people in the EU

- PMLiVE

Start SMART

Collecting the right data in the right way for the right reasons

Group of friends smiling together

Empowering patients through more accessible clinical trial information

Senior Medical Writer, Scott Palmer explores the challenges and solutions in enhancing patient engagement in clinical trials, from the pivotal role of healthcare professionals, to the importance of user-friendly trial...

Cuttsy + Cuttsy

- PMLiVE

PLANNING SOCIAL MEDIA CAMPAIGNS – THE HEALTHCARE MARKETER’S GUIDE

Social media channels are now a key part of how brands and audiences connect and communicate. Audiences are no longer passive recipients to brand messaging; two-way communication is an expectation...

IGNIFI

- PMLiVE

Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine approved by MHRA

The UK regulator has approved four versions of the updated vaccine for adults and children from infancy

- PMLiVE

Merck’s Keytruda combination recommended by NICE for advanced gastric cancer

More than 6,500 new cases of gastric cancer are diagnosed in the UK every year

- PMLiVE

Study reveals GSK’s new recombinant shingles vaccine could reduce dementia risk

Shingrix reduced dementia diagnoses by 17% compared to Merck & Co’s Zostavax after six years

- PMLiVE

Johnson & Johnson’s Rybrevant recommended by CHMP for pre-treated advanced NSCLC

Non-small lung cancer accounts for up to 85% of all lung cancer cases

- PMLiVE

Creativity at Cannes Lions 2024

Across almost every sector, brands are multiplying their investment in creativity

- PMLiVE

AstraZeneca signs exclusive licensing deal worth over $500m for Pinetree’s EGFR degrader

The candidate has shown promising preclinical anti-tumour activity in drug- and TKI-resistant tumours

- PMLiVE

Pfizer’s one-time haemophilia B gene therapy Durveqtix granted EC approval

More than 42,000 people globally are living with the rare bleeding disorder

- PMLiVE

AbbVie’s IL-23 inhibitor Skyrizi approved by EC to treat ulcerative colitis in adults

The form of inflammatory bowel disease is estimated to affect five million people globally

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links